← All trials
NCT04662099
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2020
- Primary completion
- Dec 30, 2022
- Completion date
- Dec 30, 2023
- First posted
- Dec 10, 2020
- Last posted
- Dec 10, 2020
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Huazhong University of Science and TechnologyReponsible party - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Wuhan Sian Medical Technology Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.